Agentix Company Description

Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States.

It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases.

The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019.

Agentix Corp. was founded in 2020 and is based in Dana Point, California.

Agentix Corp.

Country	United States
Founded	2020
Industry	Biotechnology
Sector	Healthcare
CEO	Riazul Huda

Contact Details

Address: 32932 Pacific Coast Highway Dana Point, Nevada 92629 United States
Phone	321 299 2014
Website	agentixcorp.com

Stock Details

Ticker Symbol	AGTX
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	April - March
Reporting Currency	USD
ISIN Number	US00848A1034
SIC Code	2830

Key Executives

Name	Position
Riazul Huda	Chief Executive Officer, Chief Financial Officer and Director
Martin Schroeder	Chief Scientific Officer and Member of Scientific Advisory Board